23:18 , Jan 18, 2019 |  BioCentury  |  Finance

Broken window

A combination of bad calendar luck and the U.S. government shutdown is trending toward this being one of the slowest Januarys for biotech public financings in recent years. But a few deals are getting done...
20:41 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Jan. 16 that...
14:50 , Jan 16, 2019 |  BC Extra  |  Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Wednesday that it...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed on Jan. 3 to acquire the bellwether for $74 billion....
19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
00:57 , Jan 4, 2019 |  BC Extra  |  Company News

BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across...
14:08 , Jan 3, 2019 |  BC Extra  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed Thursday to acquire the bellwether for $74 billion. BMS cited...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...